The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Authors
Vishwanathan, KDickinson, P
So, K
Thomas, K
Chen, Y
de Castro Carpeno, J
Dingemans, A
Kim, H
Kim, J
Krebs, Matthew G
Yang, J
Bui, K
Weilert, D
Harvey, R
Affiliation
Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA, USAIssue Date
2018-01-30
Metadata
Show full item recordAbstract
We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported.Citation
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. 2018, Br J Clin PharmacolJournal
British Journal of Clinical PharmacologyDOI
10.1111/bcp.13534PubMed ID
29381826Type
ArticleLanguage
enISSN
1365-2125ae974a485f413a2113503eed53cd6c53
10.1111/bcp.13534
Scopus Count
Collections
Related articles
- An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
- Authors: Li J, Rockich K, Yuska B, Zhou G, Epstein N, Punwani N, Chen X, Yeleswaram S
- Issue date: 2020 Nov
- Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
- Authors: Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K, Narasimhan N
- Issue date: 2020 Feb
- Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
- Authors: Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R
- Issue date: 2016 Oct
- Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
- Authors: Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T
- Issue date: 2011
- Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
- Authors: Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D
- Issue date: 2015 Sep